CAS Number113852-37-2
SynonymsCidovir (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine HPMPC Vistide; ({[(2S)-1-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-3-hydroxy-2-propanyl]oxy}methyl)phosphonic acid; Vistide; ({[(2S)-1-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; Cidofovir; (S)-(3-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid; (S)-[[2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic Acid; MFCD00866936; Cidofovir hydrate; GS-504
Molecular FormulaC8H14N3O6P
Molecular Weight279.19 (anhydrous basis)
Purity≥98 (HPLC)%
Density1.8±0.1 g/cm3
Boiling Point609.5±65.0 °C at 760 mmHg
Melting Point260ºC
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 113852-37-2 |
| Catalog No. | 2A-9050787 |
| Chinese Name | 西多福韦 |
| Synonyms | Cidovir (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine HPMPC Vistide; ({[(2S)-1-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-3-hydroxy-2-propanyl]oxy}methyl)phosphonic acid; Vistide; ({[(2S)-1-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; Cidofovir; (S)-(3-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid; (S)-[[2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic Acid; MFCD00866936; Cidofovir hydrate; GS-504 |
| Molecular Formula | C8H14N3O6P |
| Molecular Weight | 279.19 (anhydrous basis) |
| Purity | ≥98 (HPLC) |
| Density | 1.8±0.1 g/cm3 |
| Boiling Point | 609.5±65.0 °C at 760 mmHg |
| Melting Point | 260ºC |
| Appearance | powder |
| Storage Condition | room temp |
| Application | Cidofovir can control cytomegalovirus CMV replication by inhibiting viral DNA polymerase activity. |
| HTC | 2933599090 |
| PubChem ID | 329775105 |
| MDL Number | MFCD17215968 |
| SMILES | O.NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1 |
| InChI | 1S/C8H14N3O6P.H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);1H2/t6-;/m0./s1 |
| InChI Key | KLJYJZIIJLYJNN-RGMNGODLSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | transportation |
| MSDS | msds/50787_1_113852_37_2.pdf |
| Bioactivity | Cidofovir is an anti-CMV drug which can suppress CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription.IC50 Value:Target: CMV DNA polymerasein vitro: The minimum concentrations of (S)-HPMPC required to inhibit CMV plaque formation by 50% was microgram/ml. The selectivity indices of (S)-HPMPC, as determined by the ratio of the 50% inhibitory concentration for cell growth to the 50% inhibitory concentration for plaque formation for CMV (AD-169 strain), was 1,500 [1]. The time course of uptake of HPMPC into Vero cells was linear between 10 and 75 min and proportional to the concentration in the medium from 10(-6) to 10(-2) M. HPMPC uptake was temperature sensitive and the rate of uptake was considerably lower at 27 degrees than at 37 degrees and almost totally inhibited at 4 degrees [2]. in vivo: Levels of cidofovirin serum following intravenous infusion were dose proportional over the dose range of 1.0 to 10.0 mg/kg of body weight and declined biexponentially with an overall mean ± standard deviation terminal half-life of 2.6 ± 1.2 h (n = 25). Approximately 90% of the intravenous dose was recovered unchanged in the urine in 24 h. The overall mean ± standard deviation total clearance of the drug from serum (148 ± 25 ml/h/kg; n = 25) approximated renal clearance (129 ± 42 ml/h/kg; n = 25), which was significantly higher (P < 0.001) than the baseline creatinine clearance in the same patients (83 ± 21 ml/h/kg; n = 12) [3]. Positive CMV urine cultures reverted to negative in 2 of 8 patients receiving doses of < or = 1.5 mg/kg twice weekly and 11 of 13 patients receiving higher doses. Cidofovir has in vivo anti-CMV activity demonstrated by prolonged clearing of CMV viruria, although this observation is tempered by the fact that clearance of viremia could not be demonstrated [4].Toxicity: Patients receiving 0.5 or 1.5 mg/kg twice weekly experienced no serious toxicity. The first two patients who received 5 mg/kg twice weekly developed glycosuria and 2+ proteinuria. Subsequent patients received concomitant probenecid to attempt to ameliorate renal toxicity [4].Clinical trial: FDA approved drug Related Catalog Signaling Pathways >> Anti-infection >> CMV Research Areas >> Infection References [1]. Snoeck R, et al. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988 Dec;32(12):1839-44. [2]. Connelly MC, et al. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem Pharmacol. 1993 Sep 14;46(6):1053-7. [3]. Cundy KC, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995 Jun;39(6):1247-52. [4]. Polis MA, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995 Apr;39(4):882-6. Chemical & Physical Properties Density 1.8±0.1 g/cm3 Boiling Point 609.5±65.0 °C at 760 mmHg Melting Point 260ºC Molecular Formula C8H14N3O6P Molecular Weight 279.187 Flash Point 322.4±34.3 °C Exact Mass 279.062012 PSA 157.71000 LogP -3.37 Vapour Pressure 0.0±4.0 mmHg at 25°C Index of Refraction 1.656 InChIKey VWFCHDSQECPREK-LURJTMIESA-N SMILES Nc1ccn(CC(CO)OCP(=O)(O)O)c(=O)n1 Storage condition room temp |
| Use of | Properties Name cidofovir anhydrous Synonym More Synonyms Cidofovir Biological Activity Related Catalog Signaling Pathways >> Anti-infection >> CMV Research Areas >> Infection References [1]. Snoeck R, et al. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988 Dec;32(12):1839-44. [2]. Connelly MC, et al. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem Pharmacol. 1993 Sep 14;46(6):1053-7. [3]. Cundy KC, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995 Jun;39(6):1247-52. [4]. Polis MA, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995 Apr;39(4):882-6. Chemical & Physical Properties Molecular Formula C8H14N3O6P Exact Mass 279.062012 PSA 157.71000 LogP -3.37 Index of Refraction 1.656 InChIKey VWFCHDSQECPREK-LURJTMIESA-N Storage condition room temp |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (Cidofovir hydrate) IMDG Code: TOXIC SOLID, ORGANIC, N.O.S. (Cidofovir hydrate) International air transport hazard regulations: Toxic solid, organic, n.o.s. (Cidofovir hydrate) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| 1-Phenyl-3-(pyrrolidin-1-yl)propan-1-amine | 113640-37-2 | 2A-9050771 |
| N3,N3-Diethyl-1-phenyl-1,3-propanediamine | 113640-41-8 | 2A-9050772 |
| Fura 2 pentapotassium | 113694-64-7 | 2A-9050774 |
| Olopatadine | 113806-05-6 | 2A-9050783 |
| (2R)-(-)-Glycidyl tosylate | 113826-06-5 | 2A-9050785 |
| 2-Deoxy-alpha-L-erythro-pentopyranose | 113890-34-9 | 2A-9050789 |
| Cefozopran hydrochloride | 113981-44-5 | 2A-9050796 |
| Desmethyl amolodipine | 113994-37-9 | 2A-9050798 |
| 4-[2-[4-(Bishexadecylamino)phenyl]ethenyl]-1-methylpyridinium iodide | 114041-00-8 | 2A-9050804 |
| (E)-3-Cyclohexyl-2-propen-1-ol | 114096-03-6 | 2A-9050808 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS